Featured Story By Ben Adams Germany’s Merck, looking to beef up its cancer pipeline and move beyond its checkpoint inhibitor Bavencio in the future, has signed up to in-license a late-stage oncology assert from Swiss biotech Debiopharm. read more |
| |
---|
|
Top Stories By Amirah Al Idrus OrbiMed banked $3.5 billion in its latest raise, a sum that will be divided among three private investment funds, including one focused on early-stage companies in North America and Europe and a second aimed at companies of various stages in Asia. read more By Nick Paul Taylor The FDA has accepted a filing for approval of Merck’s P2X3 receptor antagonist gefapixant for review. Merck is seeking approval on the basis of phase 3 trials that linked the oral drug to improvements in several measures of chronic cough symptoms but confirmed tolerability concerns. read more Sponsored By: Taconic Biosciences Humanized immune system mice are revolutionary tools for the development of oncology therapeutics, but their use has been limited for some applications by impaired human myeloid cell differentiation. read more By Ben Adams Using antibody-drug conjugate tech against cancer targets has become hot property in recent years, and a new Chinese biotech is cashing in on the craze. read more By Amirah Al Idrus With another $106 million in the bank, heart-focused Tenaya Therapeutics is ready to talk targets. The series C funding will propel several preclinical programs toward the clinic, including a gene therapy for hypertrophic cardiomyopathy, as well as set up a site in the Bay Area to manufacture vectors to deliver its treatments. read more By Nick Paul Taylor SalioGen Therapeutics has raised $20 million to validate a platform designed to eliminate barriers to the use of gene therapies. The series A will support preclinical validation of mammal-derived enzyme saliogase in the creation of in vivo gene therapies for familial hypercholesterolemia and inherited macular degeneration. read more By Arlene Weintraub Three Johns Hopkins research groups designed bispecific antibodies so they simultaneously bind to tumor antigens and T cells, resulting in drugs that could offer off-the-shelf immuno-oncology to a wide variety of cancer patients, they argued. The drugs showed promising efficacy in preclinical models. read more By Conor Hale Rebus Biosystems has launched what it describes as its new “spatial omics” system, designed to give researchers a closer look at the output of individual cells across tissue samples. read more By Eric Sagonowsky A month after Johnson & Johnson's COVID-19 vaccine posted positive data in a phase 3 study, the shot is ready for prime time. After a key FDA panel unanimously endorsed the vaccine late Friday, the agency signed off on its emergency use Saturday. read more | Experts in our field with 20+ years’ experience in Viral Vector & Plasmid DNA manufacture. Now part of the Cognate BioServices family, your CDMO partner from concept to commercial for cell & gene therapy products. Request a call back. |
Enrollment Showcase Sponsored by: University of Florida College of Pharmacy Learn about the Top 5-Ranked UF College of Pharmacy’s online graduate programs in pharmaceutical outcomes & policy. Select from five specializations, including the new pharmaceutical value assessment & communication option. Over half of graduates progress to a new role within one year. Register now. |
| |
---|
|
Resources Sponsored By: Acorn AI Unlock competitive advantage with AI and advanced analytics. Sponsored By: EVERSANA Mature brands lost billions in revenue and value during COVID, but with the right strategy, pharma can rebound and reignite revenue. Learn How. Sponsored By: BC Platforms Download our whitepaper to learn how BC Platforms has leveraged our technical expertise to offer robust and comprehensive solutions to maximize RWD ROI. Sponsored By: Thermo Fisher Scientific Involved in vaccine development? Check out this timely infographic detailing the history of vaccines, key development milestones, and what challenges remain. Sponsored By: Blue Matter, strategic consultants in the life sciences A look ahead at how cell-based therapies in oncology will advance during 2021-22: research, regulatory, and commercial milestones. Sponsored by: Baxter BioPharma Solutions While service directories are filled with CMOs claiming vaccine fill-finish experience, the logistical challenges resulting from seasonal product are unique and it is important that outsourcing partners can ensure quality and on-time delivery. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Premier Research Browse the latest learnings and insights from our clinical development professionals. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. |